Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defenseImmunology Review Published on 2024-07-312024-09-05 Journal: Frontiers in immunology [Category] update2024, [키워드] epigenetics FOXP3 Hematopoiesis Immune homeostasis Metabolic regulation tissue repair Tregs [DOI] 10.3389/fimmu.2024.1444533 PMC 바로가기 [Article Type] Immunology Review
Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis Barticle Published on 2023-11-132024-09-05 Journal: BMC Gastroenterology [Category] update2024, [키워드] fatty acid metabolism HBV Hepatocellular carcinoma Prognosis Tregs [DOI] 10.1186/s12876-023-03026-5 PMC 바로가기 [Article Type] article
Unique molecular signatures sustained in circulating monocytes and regulatory T cells in convalescent COVID-19 patientsArticle Published on 2023-05-052024-09-05 Journal: Clinical immunology (Orlando, Fla.) [Category] update2024, [키워드] COVID-19 Monocytes Sustained immunity Tregs [DOI] 10.1016/j.clim.2023.109634 PMC 바로가기 [Article Type] Article
Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosyarticle Published on 2023-04-302024-09-01 Journal: Frontiers in immunology [Category] 한센병, [키워드] IL-10 leprosy PD-1 T cell anergy T cells Tregs [Article Type] article
Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathwaysArticle Published on 2023-04-212023-06-12 Journal: Journal of Translational Medicine [Category] B형 간염, Fulltext, [키워드] CCR4 CD4 and CD8 T cells CHB Tregs [DOI] 10.1186/s12967-023-04104-8 PMC 바로가기
Low BALF CD4 T cells count is associated with extubation failure and mortality in critically ill covid-19 pneumonia낮은 BALF CD4 T 세포 수는 중환자의 covid-19 폐렴에서 발관 실패 및 사망률과 관련이 있습니다Article Published on 2022-12-012022-09-11 Journal: Annals of Medicine [Category] 바이오마커, 진단, [키워드] affected alveolar alveolar macrophage analysed average BALF BALF CD4 T-cells count baseline Biomarker bivariate analysis Bronchoalveolar lavage fluid caspase caspase-3 cause CD4 CD4 T cell CD4 T-cell Characteristics clinical Clinical characteristics conducted COVID-19 COVID-19 patients COVID-19 pneumonia COVID-19 pneumonia patient COVID-19 pneumonia patients Critically ill critically ill COVID-19 patients Critically ill COVID-19 pneumonia D-dimer D-dimer level eight enrolled extubation failure. groups help IL-17 IL-6 immunopathology IMPROVE Indonesia intubation Invasive mechanical ventilation Laboratory lung Macrophage material Mortality no significant difference no significant differences outcome Patient performed Pneumonia profile Referral reported right lung severe pneumonia severity significant differences significantly survived T-cells Tertiary Tregs understanding was performed were measured [DOI] 10.1080/07853890.2022.2095012 PMC 바로가기 [Article Type] Article
Integrated Analysis of Cytokine Profiles in Malaria Patients Discloses Selective Upregulation of TGF-β1, β3, and IL-9 in Mild Clinical PresentationArticle Published on 2022-10-212024-08-29 Journal: International Journal of Molecular Sciences [Category] 말라리아, [키워드] malaria pattern parasite pro-inflammatory cytokines regulatory cytokines. Tregs
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccinationArticle Published on 2022-08-312022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] alteration anti-CD20 anti-CD20 therapy antibody applied approach B cell caused CD4 Cellular immune response cellular immunity characterized Complete decrease Delta disorder dosage Effect elicit Frequency healthy controls humoral humoral immune response immune Immune cell immune cells immune response Immunosuppression implication information investigated mean treatment duration Multiple multiple sclerosis neutralization capacity Ofatumumab ofatumumab. omicron pandemic Patient preserved Regulatory T cell SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 variant sclerosis subcutaneously subpopulation sustained T cell T cell response T helper Th1 titer treated treated patient Treatment Tregs vaccination was impaired wild type [DOI] 10.3389/fimmu.2022.980526 PMC 바로가기
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral SclerosisRandomized Controlled Trial Published on 2022-08-292022-10-05 Journal: Neurology® neuroimmunology & neuroinflammation [Category] 바이오마커, 임상, [키워드] 1:1 ALS assigned autologous average baseline changed class classification clinical study Combined conducted COVID-19 pandemic Disease progression Dose escalation dose-escalation doses effective elevated enrolled Evidence extension Good group help IL-2 Inflammation injection intervals Lateral Sclerosis LDL Leukapheresis low-density marker matching placebo Open-label oxidative stress oxidized participant Patient Person Placebo Practice progression provide Randomized controlled trial Randomly RCT receive receptor Regulatory reliability Safe slow disease suppressive function T-lymphocyte therapy Treatment Treg Tregs Year [DOI] 10.1212/NXI.0000000000200019 PMC 바로가기 [Article Type] Randomized Controlled Trial
A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial – implications for therapeutic immune modulationResearch article Published on 2022-08-182022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 변종, 임상, [키워드] 1:1 Activation Adaptive immune response addition adverse event ARCADIA assigned AZD1656 Clinical improvement clinical trial Complete COVID-19 cytokine Czech Republic Day death decrease diabetes diabetic patient diabetic patients dose double-blind duration of hospitalisation Efficacy Excalibur False positive finding Full Analysis Set funding Glucokinase activator group homeostatic hospital hospital discharge hospitalised identify immune Immune cell immune modulation immune response Immunochemistry immunomodulatory effect Immunophenotyping implication indicated Innovation investigated involved less Medicine multicentre nine no difference Patient phase Phase 2 Placebo placebo-controlled placebo-controlled clinical trial primary analysis primary endpoint pro-inflammatory randomised Randomly receive recruited reduction in Registered regulatory T cells required risk Romania SARS-CoV-2 screened statistically significant difference suggested Tablet the placebo group therapeutic therapeutic effect treated Treatment treatment allocation Tregs Trial usual care with COVID-19 [DOI] 10.1016/j.eclinm.2022.101604 [Article Type] Research article